Biopharmaceutical
100 Most Popular
Pharmaceutical

AbbVie

$68.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.29 (0.42%) Today
-$0.04 (-0.06%) As of 7:19 PM EDT after-hours

Why Robinhood?

You can buy or sell AbbVie and other stocks, options, ETFs, and crypto commission-free!

About ABBV

ABBVIE INC., also called AbbVie, is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as as well as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. Read More The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Employees
30,000
Headquarters
North Chicago, Illinois
Founded
2011
Market Cap
101.32B
Price-Earnings Ratio
19.64
Dividend Yield
4.28
Average Volume
11.14M
High Today
$68.82
Low Today
$68.10
Open Price
$68.14
Volume
9.81M
52 Week High
$100.23
52 Week Low
$65.06

Collections

Biopharmaceutical
100 Most Popular
Pharmaceutical
Health
Manufacturing
Cancer Prevention
Technology
2013 IPO

ABBV News

Barron'sJul 16

Allergan Stock Won’t Rise Much More, Analyst Says, in Looking at Deal With AbbVie

1,152
BenzingaJul 10

Analyst: CytomX Therapeutics Validated By AbbVie Decision

1,814
Wall Street JournalJul 6

Plan on More Pharma Megamergers

321

ABBV Earnings

$1.44
$1.69
$1.95
$2.20
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
$2.20 per share
Actual
Available Jul 26, Pre-Market

Popular Stocks

More ABBV News

Barron'sJul 5

The Stock Market May Be Pointing to Trump’s Reelection

1,477
The EconomistJul 5

Investors and regulators fall out of love with colossal deals

568
Barron'sJul 2

AbbVie’s Allergan Acquisition Sowed Doubts on Wall Street. Some Analysts Are Coming Around.

2,372
Barron'sJun 28

AbbVie Is Buying Allergan. That’s Not the Right Remedy for the Stock.

2,533
Washington PostJun 28

Almost $500 Billion of Megadeals Get Panned Instantly

1,850
ReutersJun 27

US loan market ready to feast on AbbVie's jumbo US$38bn bridge loan

1,563
New York TimesJun 27

Drugmaker Deals Are Near Record Pace in 2019, but Investors Don’t Love Them All

783
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.